2008;39:2432 2438. of Smoking: A Report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004. 364. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008:CD006103. apy for smoking cessation. Cochrane Database Syst Rev. 2008:CD000146. 366. Fiore MC, Jean CR, Baker TB, Bailey WC, Benowitz N, Curry SJ, Dorfman SF, Froelicher ES, Goldstein MG, Healton CG, Henderson PN, Heyman RB, Koh HK, Kottke TE, Lando HA, Mecklenburg RE, Mermeistein RJ, Mullen PD, Orleans CT, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: US Department of Health and Human Services, Public Health Service. April 2009. 367. US Preventive Services Task Force. Counseling, and interventions to prevent tobacco use, and tobacco-caused disease in adults, and pregnant women: U.S. Preventive Services Task Force reaffirmation recommenda- tion statement. Ann Intern Med. 2009;150:551 555. of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44:588 597. Meschia et al Guidelines for the Primary Prevention of Stroke 3817 369. Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork AC, Aubin HJ. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation: results from four European countries. Eur J Public Health. 2009;19:650 654. 370. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrilla- tion. Med Clin North Am. 2008;92:17 40, ix. 371. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983 988. 372. Stroke Risk in Atrial Fibrillation Working Group. 